The role of Aurora-A inhibitors in cancer therapy

Annals of Oncology

Volumn 18, Issue SUPPL. 6, 2007, Pages

  Agnese, V ^a   Bazan, V ^a   Fiorentino, F P ^a   Fanale, D ^a   Badalamenti, G ^a   Colucci, G ^b   Adamo, V ^c   Santini, D ^d   Russo, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Aurora A; Cancer treatment; Kinase inhibitor; Mitosis; Small molecule

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AT 9283; AURORA A KINASE; AURORA A KINASE INHIBITOR; AURORA KINASE INHIBITOR; CHR 3520; CTK 110; CYC 116; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; ENMD 981693; HESPERADIN; JNJ 7706621; MLN 8054; MP 235; MP 529; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; NOCODAZOLE; PACLITAXEL; PHA 680632; PHA 739358; PHOSPHOTRANSFERASE INHIBITOR; R 763; SNS 314; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AURORA KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE;

ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CELL CYCLE REGULATION; CLINICAL TRIAL; CONFERENCE PAPER; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; MITOSIS INHIBITION; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; ANIMAL; BIOSYNTHESIS; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 35748945448     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm224     Document Type: Conference Paper

References (45)

1. Tao W et al. Induction of apoptosis by an inhibitor of the mitotic kinesin KSP requires both activation of the spindle assembly checkpoint and mitotic slippage. Cancer Cell 2005; 8: 49-59.
2. Marcus Al et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem 2005; 280: 11569-11577.
3. McEwen BF et al. CENP-E is essential for reliable bioriented spindle attachment, but chromosome alignment can be achieved via redundant mechanisms in mammalian cells. Mol Biol Cell 2001; 12: 2776-2789.
4. Sumara I et al. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 2004; 14: 1712-1722.
5. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A 2003; 100: 5789-5794.
6. Tanaka T, Kimura M, Matsunaga K et al. Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999; 59: 2041-2044.
7. Sakakura C, Hagiwara A, Yasuoka R et al. Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation. Br J Cancer 2001; 84: 824-831.
8. Bischoff JR, Anderson L, Zhu Y et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998; 17: 3052-3065.
9. Sen S, Zhou H, Zhang RD et al. Amplification/overexpression of a mitotic kinase gene in human bladder. J Natl Cancer Inst 2002; 94: 1320-1329.
10. Zhu J, Abbruzzese JL, Izzo J et al. AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells. Cancer Genet Cytogenet 2005; 159: 10-17.
11. Gritsko TM, Coppola D, Paciga JE et al. Activation and overexpression of centrosome kinase BTAK/Aurora A, in human ovarian cancer. Clin Cancer Res 2003; 9: 1420-1426.
12. Pihan GA, Purohit A, Wallace J et al. Centrosome defects can account for cellular and genetic changes that characterize prostate cancer progression. Cancer Res 2001; 61: 2212-2219.
13. Tanaka E, Hashimoto Y, Ito T et al. The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11(5): 1827-1834.
14. Katayama H, Brinkley WR, Sen S. The Aurora kinases: Role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003; 22(4): 451-464.
15. Castro A, Arlot-Bonnemains Y, Vigneron S et al. APC/Fizzy-related targets aurora-A kinase for proteolysis. EMBO Rep 2002; 3: 457-462.
16. Littepage, LE, Ruderman JV. Identfication of a new APC/C recogniton domain, the A box, which is required for the Cdh 1-dependent destruction of the kinase aurora-A during mitotic exit. Genes Dev 2002; 16: 2274-2285.
17. Littlepage LE, Wu H, Andresson T et al. Identification of phosphorylated residues that affect the activity of the mitotic kinase aurora-A. Proc Natl Acad Sci U S A 2002; 99: 15440-15445.
18. Kiat LS, Hui KM, Gopalan G. Aurora-A kinase interacting protein (AJP), a novel negative regulator of human aurora-A kinase. J Biol Chem 2002; 277: 45558-45565.
19. Katayama H, Zhou H, Li Q et al. Interaction and feedback regulation between STK15/BTAK/aurora-A kinase and protein phosphatase 1 through mitotic cell division cycle. J Biol Chem 2001; 276: 46219-46224.
20. Marumoto T, Zhang D, Saya H. Aurora-A - a guardian of poles. Nat Rev Cancer 2005; 50(1): 42-50.
21. Hirota T et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003; 114: 585-598.
22. Marumoto T et al. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003; 278: 51786-51795.
23. Dutertre S et al. Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2-M transition. J Cell Sci 2004; 117: 2523-2531.
24. Garrett S, Auer K, Compton DA, Kapoor TM. hTPX2 is required for normal spindle morphology and centrosome integrity during vertebrate cell division. Curr Biol 2002; 12: 2055-2059.
25. Ditchfied C et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003; 161: 267-280.
26. Hauf S et al. The small molecule Hesperadin reveals a role for Aurora B in correctng kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol 2003; 161: 281-294.
27. Andrews PD, Knatko E, Moore WJ, Swedlow JR. Mitotic mechanics: The auroras come into view. Curr Opin Cell Biol 2003; 15: 672-683.
28. Kunitoku N et al. CENP-A phosphorylation by Aurora-A in prophase is required for enrichment of Aurora-B at inner centromeres and for kinetochore function. Dev Cel 2003; 5: 853-864.
29. - cells. EMBO J 2002; 21: 483-492.
30. Anand S, Penrhyn-Lowe S, Venkitaraman AR. AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol. Cancer Cell 2003; 3: 51-62.
31. Zhang D et al. Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models. Oncogene 2004; 23: 8720-8730.
32. Honda K et al. Degradation of human Aurora2 protein kinase by the anaphase-promoting complex-ubiquitin proteasome pathway. Oncogene 2000; 19: 2812-2819.
33. Castro A et al. The D-Box-activating domain (DAD) is a new proteolysis signal that stimulates the silent D-Box sequence of Aurora-A. EMBO Rep 2002; 3: 1209-1214.
34. Bischoff JR et al. A homologue of Drosophilla aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998; 17: 3052-3065.
35. Sen S, Zhou H, White RA. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 1997; 14: 2195-2200.
36. Goepfert TM et al. Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis. Cancer Res 2002; 62: 4115-4122.
37. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 2065-2071.
38. Chen SS, Chang PC, Cheng YW et al. Suppression of the STK1 5 oncogenic activity requires a transactivation-independent p53 function. EMBO J 2002; 21: 4491-4499.
39. Katayama H et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nature Genet 2004; 36: 55-62.
40. Liu Q et al. Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J Biol Chem 2004 doi: 10. 1074/jbc,M406802200.
41. Jiang Y, Zhang Y, Lees E, Seghezzi W. AuroraA overexpression overrides the mitotic spindle checkpoint triggered by nocodazole, a microtubule destabilizer. Oncogene 2003; 22: 8293-8301.
42. Emanuel S, Rugg CA, Gruninger RH et al. The in vitro and in vivo effects of JNJ-7706621: A dual inhibitor of cyclin-dependent kinases and aurora kinases. Cancer Res 2005; 65(19): 9038-9046.
43. Godl K, Gruss OJ, Eickhoff J et al. Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. Cancer Res 2005; 65(15): 6919-6926.
44. Harrington EA et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo, Nat Med 2004; 10: 262-267.
45. Margolis RL, Lohez OD, Andreassen PR. G1 tetraploidy checkpoint and the suppression of tumorigenesis. J Cell Biochem 2003; 88: 673-683.